Open AccessTherapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia
Author(s) -
Sanjay Mohan,
Michael J. Clemente,
Manuel Afable,
Heather Cazzolli,
Nelli Bejanyan,
Marcin W. Wlodarski,
Alan E. Lichtin,
Jaroslaw P. Maciejewski
Publication year - 2009
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2009.009191
Subject(s) - cd52 , alemtuzumab , immunology , medicine , cytopenia , cytotoxic t cell , cd8 , chronic lymphocytic leukemia , leukemia , population , bone marrow , antibody , immune system , biology , biochemistry , environmental health , in vitro
T-cell large granular lymphocytic leukemia is a clonal proliferation of cytotoxic T-lymphocytes which often results in severe cytopenia. Current treatment options favor chronic immunosuppression. Alemtuzumab, a humanized monoclonal antibody against glycophosphatidylinositol-anchored CD52, is approved for patients refractory to therapy in other lymphoid malignancies.